Literature DB >> 14767995

Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice.

Shan Zeng1, Nikki Feirt, Michael Goldstein, James Guarrera, Nikalesh Ippagunta, Udeme Ekong, Hao Dun, Yan Lu, Wu Qu, Ann Marie Schmidt, Jean C Emond.   

Abstract

Hepatic ischemia/reperfusion (I/R) injury associated with liver transplantation and hepatic resection is characterized by hepatocellular damage and a deleterious inflammatory response. In this study, we examined whether receptor for advanced glycation end product (RAGE) activation is linked to mechanisms accentuating inflammation on I/R in a murine model of total hepatic ischemia. Animals treated with soluble RAGE (sRAGE), the extracellular ligand-binding domain of RAGE, displayed increased survival after total hepatic I/R compared with vehicle treatment. TUNEL assay and histologic analysis revealed that blockade of RAGE was highly protective against hepatocellular death and necrosis on I/R; in parallel, proliferating cell nuclear antigen was enhanced in livers of mice treated with sRAGE. Rapid activation of p38, p44/42, stress-activated protein kinase and c-Jun N-terminal kinase mitogen-activated protein kinases, signal transducer and activator of transcription-3, and nuclear translocation of activator protein-1 was evident at early times on I/R. In the remnants of sRAGE-treated livers, however, activation of each of these signaling and transcription factor pathways was strikingly decreased. sRAGE-treated remnants displayed enhanced activation of nuclear factor kappaB, in parallel with increased transcripts for the proregenerative cytokine, tumor necrosis factor-alpha. In conclusion, these data suggest that RAGE modulates hepatic I/R injury, at least in part by activation of key signaling pathways linked to proinflammatory and cell death-promoting responses. We propose that blockade of this pathway may represent a novel strategy to attenuate injury in hepatic I/R and to facilitate regeneration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767995     DOI: 10.1002/hep.20045

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  71 in total

1.  Macrophage activation by factors released from acetaminophen-injured hepatocytes: potential role of HMGB1.

Authors:  Ana-Cristina Dragomir; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2011-04-14       Impact factor: 4.219

2.  Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.

Authors:  Noah A Cohen; Shan Zeng; Adrian M Seifert; Teresa S Kim; Eric C Sorenson; Jonathan B Greer; Michael J Beckman; Juan A Santamaria-Barria; Megan H Crawley; Benjamin L Green; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Ronald P DeMatteo
Journal:  Cancer Res       Date:  2015-04-02       Impact factor: 12.701

3.  Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Béla Horváth; Sándor Bátkai; Ogyi Park; Galin Tanchian; Rachel Y Gao; Vivek Patel; David A Wink; Lucas Liaudet; György Haskó; Raphael Mechoulam; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-03-11       Impact factor: 7.376

Review 4.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

Review 5.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

6.  Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Authors:  Teresa S Kim; Michael J Cavnar; Noah A Cohen; Eric C Sorenson; Jonathan B Greer; Adrian M Seifert; Megan H Crawley; Benjamin L Green; Rachel Popow; Nagavarakishore Pillarsetty; Darren R Veach; Anson T Ku; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Shan Zeng; Ronald P Dematteo
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

Review 8.  Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

Authors:  Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

Review 9.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Expert Rev Mol Med       Date:  2009-03-12       Impact factor: 5.600

10.  Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity.

Authors:  Runkuan Yang; Keita Miki; Xin He; Meaghan E Killeen; Mitchell P Fink
Journal:  Crit Care       Date:  2009-04-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.